

Supplementary data

**Study of pro-angiogenic activity of astilbin on human umbilical vein
endothelial cells *in vitro* and zebrafish *in vivo***

Kongpeng Lv,^{a,b} Qin Ren,^a Xingyan Zhang,^a Keda Zhang,^{a,b} Jia Fei,^{b*} Tiyan Li,^{a*}

^a Shenzhen Infectious Disease Medicine Engineering Center, Shenzhen People's Hospital, 2nd Clinical Medical College of Jinan University, Shenzhen 518120, Guangdong Province, China.

^b Integrated Chinese and Western Medicine Postdoctoral Research Station, Jinan University, Guangzhou 510632, Guangdong Province, China




Figure S1. Effects of astilbin on cell viability of different human cancer cells. (A) Hep G2, (B) HT-29, (C) A549 and (D) MDA-MB-231 human cancer cells were treated with various concentrations of Ast (50-800 μM) in low serum media (0.5% FBS) culture for 24 h to 72 h. Then cell viability was detected by MTT assay. Data are presented as the percentage of the control group (mean ± SD of three independent experiments).




Figure S2. Toxicity assessment of astilbin in normal human cell line and zebrafish larvae. (A) L-02, human fetal hepatocytes and (B) HEK 293, human embryonic kidney cells were treated with various concentrations of Ast (50-200 μ M) in the media contained 10% FBS and then cultured for 24 h to 96 h. Then cell viability was detected by MTT assay. (C) LDH assay were performed after 96 h treatment in both L-02 and HEK 293 cells. (D) 24 hour post fertilization zebrafish embryos (n=15) were treated with various concentrations of Ast (30-300 μ M) for 96 h. The survival rate in each group were recorded every 24 h. Data are presented as the percentage of the control group (mean \pm SD of three independent experiments). *p<0.05 versus control group.